Nymox Pharmaceutical Corporation

Equities

NYMXF

BSP733981026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:04:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.3 ^USD	0.00%		0.00%	-49.15%

2023	Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	CI

Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019

May 15, 2019 at 03:07 pm EDT

Nymox Pharmaceutical Corporation announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 30,000 compared to USD 152,000 a year ago. Operating loss was USD 2.913 million compared to USD 2.658 million a year ago. Net loss was USD 2.870 million compared to USD 2.664 million a year ago. Basic loss per share was USD 0.04 compared to USD 0.05 a year ago.

Latest news about Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH	23-09-25	CI
Nymox Pharmaceutical Corporation announced that it has received $2 million in funding	23-08-28	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding	23-08-01	CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results	23-07-25	CI
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors	23-07-12	CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday	23-07-06	MT
Nymox Pharmaceutical Receives Delisting Notice From Nasdaq	23-07-06	MT
Nymox Pharmaceutical Corporation(OTCPK:NYMX.F) dropped from NASDAQ Composite Index	23-07-06	CI
Nymox Pharmaceutical Corporation Announces Removal of Board of Directors	23-06-27	CI
Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer	23-06-27	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Index	23-06-23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Growth Index	23-06-23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Index	23-06-23	CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Growth Index	23-06-23	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Nymox Pharmaceutical Corporation Auditor Raises 'Going Concern' Doubt	23-05-01	CI
Nymox Pharmaceutical Names Christopher Riley as CFO	23-03-21	MT
Nymox Pharmaceutical Corporation Announces Appointment of Christopher R. Riley as Chief Financial Officer	23-03-21	CI
Nymox Pharmaceutical Gets Nasdaq Extension to Comply With Listing Requirements; Shares Rise	23-03-15	MT
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH	22-12-05	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI

Chart Nymox Pharmaceutical Corporation

Duration

Period

More charts

Company Profile

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Companyâs activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a personâs level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NYMOX PHARMACEUTICAL CORPORATION	-49.15%	28.01M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.83%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research